The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations
Clinical trial NCT07632170 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07632170
- Sponsor
- Bing Han
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-11-01
- Primary completion
- 2027-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.